SCHEMBL1150199

SCHEMBL1150199

O=C(OC1C(O)C(OC(=O)c2ccccc2)C(OC(=O)c2ccccc2)C(OC(=O)c2ccccc2)C1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
F2 P00734 1/20 0.52
LGALS9 O00182 1/20 0.51
LGALS1 P09382 1/20 0.51
LGALS3 P17931 1/20 0.51
LGALS7; LGALS7B P47929 1/20 0.51
TSHR P16473 2/20 0.48
CHRNA7 P36544 2/20 0.46
KMT2A Q03164 4/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
TP53 P04637 1/20 0.44
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
PTPN1 P18031 2/20 0.43
APOBEC3A P31941 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12858819 1.00 LMNA (0.52) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL9457381 0.98 LGALS9 (0.54) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL9853793 0.94 LGALS9 (0.56) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL4963759 0.92 LMNA (0.52) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL12327664 0.92 LMNA (0.52) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL4963754 0.92 LMNA (0.52) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL12292246 0.92 LMNA (0.52) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL7154464 0.91 LMNA (0.61) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL21768324 0.91 LMNA (0.61) LMNAF2LGALS9LGALS1LGALS3
SCHEMBL7154462 0.91 LMNA (0.61) LMNAF2LGALS9LGALS1LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028719-A1 SCREENING METHODS FOR AMYLOID BETA MODULATORS WARATAH PHARMACEUTICALS INC. (CA) 2011-02-03 US disclosed
WO-2007134449-A1 SCREENING METHODS FOR AMYLOID BETA MODULATORS WARATAH PHARMACEUTICALS INC. (CA) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028719-A1 SCREENING METHODS FOR AMYLOID BETA MODULATORS APP, BACE1, IAPP LMNA 1372/4885F2 3787/4885LGALS9 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.